Investors urged to join probe into GeneDx's revenue miss and stock drop after lowered 2026 guidance.

Johnson Fistel, PLLP is investigating GeneDx Holdings Corp. following the company's report of weaker-than-expected Q1 2026 revenue and a lowered full-year revenue forecast. Despite strong test volume growth, GeneDx's revenue growth slowed, and the company cited lower reimbursement rates and underperformance in non-core areas as reasons. This led to a sharp decline in GeneDx's stock price, prompting a legal probe into potential securities law violations. Investors who suffered losses are encouraged to contact Johnson Fistel for possible recovery options.